Cascadian Therapeutics Inc. Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Seattle WA United States (1985)
Status: Acquired by Seattle Genetics (2018) → now Merck (2022)

Organization Overview

First Clinical Trial
1999
NCT00003638
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Cascadian Therapeutics Inc. | Circadian Therapeutics Ltd | Oncothyreon Canada Inc.